Illumina, Inc. announced today that John W. Thompson will join the company’s Board of Directors on May 3, 2017, bringing extensive technology leadership experience to the company.
Mr. Thompson’s executive leadership experience includes having served in chief executive officer roles at Symantec and Virtual Instruments, as well as 28 years of prior leadership experience at IBM where he held senior roles in sales, marketing, software development, and as general manager of IBM Americas. He is chairman of the board at Microsoft and has served on the corporate boards of Symantec, NIPSCO (Northern Indiana Public Service Company), Fortune Brands, Seagate Technologies, and United Parcel Service (UPS). Mr. Thompson is a member of the board of trustees for the Wetlands America Trust and formerly a member of the national board of Teach for America. In addition, he has served on several government commissions including the Financial Crisis Inquiry Commission, the National Infrastructure Advisory Council, and the Silicon Valley Blue Ribbon Task Force on Aviation Security and Technology.
“John brings a great breadth of knowledge and experience in the public and private sectors having served in such a wide range of leadership and advisory roles,” said Francis deSouza, Illumina President and Chief Executive Officer. “His wealth of technology expertise will help us continue to grow and scale our business in the years to come.”
Mr. Thompson received his B.A. in business administration from Florida A&M University and his M.S. in management science from MIT’s Sloan School of Management.
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.